Alnylam Pharmaceuticals (ALNY) reported Q1 non-GAAP net loss Thursday of $0.01 per diluted share, narrower than the $0.16 net loss a year earlier.
Analysts polled by FactSet expected a loss of $0.38.
Revenue for the quarter ended March 31 was $594.2 million, up from $494.3 million a year earlier.
Analysts surveyed by FactSet expected $588.4 million.
The company reiterated its full-year 2025 guidance of $2.05 billion to $2.25 billion for total net product revenue, and $650 million to $750 million for net revenue from collaborations and royalties.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。